Stanford University School of Medicine Researcher Criticizes FDA Plans to Reduce Oversight of Off-Label Drug Use

STANFORD, Calif.--(BUSINESS WIRE)--Proposed guidelines from the U.S. Food and Drug Administration would allow companies to market more drugs for unapproved uses and are a step in the wrong direction, said a researcher from the Stanford University School of Medicine.